Eptinezumab
- Generic Name
- Eptinezumab
- Brand Names
- Vyepti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1644539-04-7
- Unique Ingredient Identifier
- 8202AY8I7H
- Background
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). It was approved by the FDA in February 2020 for the preventive treatment of migrain...
- Indication
Eptinezumab is indicated for the preventive treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 20
- Registration Number
- NCT05045781
- Locations
- 🇨🇳
zs-hospital Shanghai, Shanghai, China
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 285
- Registration Number
- NCT04965675
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN, Firenze, Toscana, Italy
🇲🇽Centro de Investigacion Medico Biologica y de Terapia Avanzada S.C., Guadalajara, Jalisco, Mexico
🇮🇹AO Brotzu - Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza - INCIPIT - PIN, Cagliari, Sardegna, Italy
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 852
- Registration Number
- NCT04921384
- Locations
- 🇨🇳
The First Medical Center of The Chinese PLA General Hospital (301 Hospital), Beijing, Beijing, China
🇯🇵Nagamitsu Clinic, Hofu, Yamaguti, Japan
🇯🇵Shin Matsudakai Atago Hospital, Kochi-shi, Japan
Eptinezumab in Adults With Migraine and Medication Overuse Headache
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 193
- Registration Number
- NCT04772742
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇨🇳General Hospital of Northern Theater Command, Shenyang, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, China
Eptinezumab in Participants With Episodic Cluster Headache
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 231
- Registration Number
- NCT04688775
- Locations
- 🇺🇸
Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇬🇪Consilium Medulla Multiprofile Clinic, Tbilisi, Georgia
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 28
- Registration Number
- NCT04537429
- Locations
- 🇺🇸
College Park Family Care Center, Overland Park, Kansas, United States
🇺🇸Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States
🇺🇸Road Runner Research Ltd, San Antonio, Texas, United States
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 892
- Registration Number
- NCT04418765
- Locations
- 🇬🇧
Panthera Biopartners - Manchester, Manchester, England, United Kingdom
🇩🇪Synexus - Leipzig, Leipzig, Sachsen, Germany
🇩🇪Neuroplus, Mannheim, Baden-Württemberg, Germany
Eptinezumab in Healthy Japanese Subjects
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04336449
- Locations
- 🇯🇵
P-One Clinic, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 485
- Registration Number
- NCT04152083
- Locations
- 🇺🇸
Aventiv Research - Columbus, Columbus, Ohio, United States
🇺🇸Neuro-Behavioral Clinical Research Inc, North Canton, Ohio, United States
🇺🇸Excell research Inc, Oceanside, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.